戻る Agenda
Session 8: Stakeholder Voice: Biosimilar Decision Making
Session Chair(s)
Laura D. Wingate
Executive Vice President, Education, Support, and Advocacy
Crohn's & Colitis Foundation, United States
Using moderated case presentation learners will explore the decision-making process between a physician and their patient as they determine the best course of biologic/biosimilar treatment. The session will feature three treatment scenarios and discussion:
- Shared decision-making process for a biologic naïve patient
- Discussion between a patient and provider when deciding to switch from a innovator to a biosimilar
- Discussion of the nocebo effect and its impact on decision making and switching behaviors
- Dialogue around multi-switch data and real world experience in practice
Learning Objective : At the conclusion of this session, participants should be able to:
- Understand the factors that influence patient and provider decision as it relates to biosimilars
- Articulate the barriers that are impacting the decision process between patient and provider
- Comprehend the need for to offer biosimilar educational resource for both patients and providers
Speaker(s)
speaker
Francis Farraye, MD, MS
Mayo Clinic Jacksonville, United States
Director, Inflammatory Bowel Disease Center, Professor of Medicine
Speaker
Shubha Bhat, PharmD, MS
Boston Medical Center, Center for Digestive Disorders & Crohn's and Colitis, United States
Ambulatory Care Clinical Pharmacy Specialist - Gastroenterology
Speaker
Shaila Abbott
Patient Advocate, United States
Speaker
Alex Hochstrasser
Ulcerative Colitis, United States
Patient Advocate